The United States of America, as Represented by the Secretary, Department of Health and Human Services

University System of Maryland

Trustees of the Colorado School of Mines

Sanjay A Desai

Ajay D Pillai

David W M Marr

Charles D Eggleton

Tobias Sawetzki

The invention provides methods of treating or preventing malaria comprising administering to an animal an effective amount of a compound of formula I:Q-Y—R—R  (I),wherein Q, Y, R, and Rare as described herein. Methods of inhibiting a plasmodial surface anion channel of a parasite in an animal are also provided. The invention also provides pharmaceutical compositions comprising a compound represented by formula I in combination with any one or more compounds represented by formulas II, V, and VI. Use of the pharmaceutical compositions for treating or preventing malaria or for inhibiting a plasmodial surface anion channel in animals including humans are also provided. Also provided by the invention are clag3 amino acid sequences and related nucleic acids, vectors, host cells, populations of cells, antibodies, and pharmaceutical compositions.

Plasmodial surface anion channel inhibitors for the treatment or prevention of malaria

Disclosed are inhibitors of the plasmodial surface anion channel (PSAC) inhibitors and the use thereof in treating or preventing malaria in an animal such as a human, comprising administering an effective amount of an inhibitor or a combination of inhibitors. An example of such an inhibitor is a compound of formula I, or a pharmaceutically acceptable salt thereof, wherein Rto Rare as described herein.

Inhibitors of the plasmodial surface anion channel as antimalarials

The invention provides methods of treating or preventing malaria comprising administering to an animal an effective amount of a compound of formula I:Q-Y&#x2014;R&#x2014;R&#x2003;&#x2003;(I),wherein Q, Y, R, and Rare as described herein. Methods of inhibiting a plasmodial surface anion channel of a parasite in an animal are also provided. The invention also provides pharmaceutical compositions comprising a compound represented by formula I in combination with any one or more compounds represented by formulas II, V, and VI. Use of the pharmaceutical compositions for treating or preventing malaria or for inhibiting a plasmodial surface anion channel in animals including humans are also provided. Also provided by the invention are clag3 amino acid sequences and related nucleic acids, vectors, host cells, populations of cells, antibodies, and pharmaceutical compositions.

The present invention generally relates to a method for determining the dynamic viscoelastic properties of cells, more particularly to a method for rapidly determining the dynamic viscoelastic properties of healthy and unhealthy cells by determining the phase shift be the application of a modulating force to the cells and the cells' response to the modulating force.

Dynamic viscoelasticity as a rapid single-cell biomarker

The invention provides methods of treating or preventing malaria comprising administering to an animal an effective amount of a compound of formula (I): Q-Y&#x2014;R&#x2014;R2 (I), wherein Q, Y, R, and Rare as described herein. Methods of inhibiting a plasmodial surface anion channel of a parasite in an animal are also provided. The invention also provides pharmaceutical compositions comprising a compound represented by formula (I) in combination with any one or more compounds represented by formulas II, V, and VI. Use of the pharmaceutical compositions for treating or preventing malaria or for inhibiting a plasmodial surface anion channel in animals including humans are also provided. Also provided by the invention are clag3 amino acid sequences and related nucleic acids, vectors, host cells, populations of cells, antibodies, and pharmaceutical compositions.

Disclosed are inhibitors of the plasmodial surface anion channel (PSAC) inhibitors and the use thereof in treating or preventing malaria in an animal such as a human, comprising administering an effective amount of an inhibitor or a combination of inhibitors. An example of such an inhibitor is a compound of formula I, Formula (I) or a pharmaceutically acceptable salt thereof, wherein Rto Rare as described herein. 

Growing community of inventors

Potomac, MD, United States of America

Sanjay A Desai